Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 0.96 |
| ▸ | MAPT | P10636 | 6/20 | 0.96 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.96 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.96 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.96 |
| ▸ | TP53 | P04637 | 3/20 | 0.96 |
| ▸ | RAD52 | P43351 | 3/20 | 0.96 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.96 |
| ▸ | HTR1A | P08908 | 2/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.96 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.96 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.96 |
| ▸ | DRD2 | P14416 | 2/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.96 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.96 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoperazine SCHEMBL29603012 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL24866 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL1897003 | 0.98 | FPR2 (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL41194 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29430171 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL23039392 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL341516 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL29579627 | 0.97 | LMNA (1.00) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL466955 | 0.96 | FPR2 (0.96) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 | |
| Trifluoperazine SCHEMBL28329317 | 0.93 | FPR2 (0.90) | FPR2LMNAMAPTSMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2024-11-19 | — | — | US | disclosed |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2023-08-17 | — | — | US | disclosed |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | CAMP4 THERAPEUTICS CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| US-20210061837-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2021-03-04 | — | — | US | disclosed |
| US-20210061837-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION | 2021-03-04 | — | — | US | disclosed |
| WO-2019195789-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | CAMP4 THERAPEUTICS CORPORATION (US) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061837-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | FPR2 2716/4885LMNA 546/4885MAPT 651/4885 |
| US-20230257410-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | FPR2 2716/4885LMNA 546/4885MAPT 651/4885 |
| US-12145963-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | FPR2 2716/4885LMNA 546/4885MAPT 651/4885 |
| US-20250034193-A1 | PHENOTHIAZINE DERIVATIVES AND USES THEREOF | RPLP2, RPS2, RPLP1 | FPR2 2716/4885LMNA 546/4885MAPT 651/4885 |
| US-11542290-B2 | Phenothiazine derivatives and uses thereof | RPLP2, RPS2, RPLP1 | FPR2 2716/4885LMNA 546/4885MAPT 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.